Enza/BI 1280.8 (gesloten)

Enzalutamide/BI, projectcode 1280.8

The overall aim of the trial is to investigate the safety and anti-tumour activity of an experimental drug BI 836845 taken together with the prostate cancer drug, enzalutamide, compared to enzalutamide given alone, in castrate resistant prostate cancer (CRPC) patients that have previously been treated and failed on docetaxel and abiraterone treatments. Initially, a tolerability and safety phase (phase Ib escalation) was performed to confirm the maximum tolerated dose (MTD), or recommended doses of both BI 836845 and enzalutamide that can be taken together.

Phase 1b has now been closed and the recruitment will start for phase II of this trial.

The randomised trial (phase II) will be an open label, parallel group study design in a 1:1 ratio to which patients will receive either BI 836845 plus enzalutamide (Arm A) at the MTD/recommended doses, or enzalutamide alone (Arm B).

In all parts of the trial safety, anti-tumour activity will be assessed, in addition to circulating tumour cells (CTC), prostate serum antigen (PSA) response and progression, pain score by Brief Pain Inventory – Short Form (BPI-SF), symptomatic skeletal events, pharmacokinetics (PK), pharmacogenomics (PGx) and biomarkers in blood and tumour tissue. In phase II a FACT-P quality of life questionnaire will also be completed.

 

Condition Intervention Phase
Prostatic Neoplasms, Castration-Resistant Drug: BI 836845
Drug: Enzalutamide
Phase 1

 

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase Ib/II, Multicentre, Open Label, Randomized Study of BI 836845 in Combination With Enzalutamide, Versus Enzalutamide Alone, in Metastatic Castration-Resistant Prostate Cancer (CRPC) Following Disease Progression on Docetaxel-Based Chemotherapy and Abiraterone

 

Primary Outcome Measures:

  • PSA response – defined as a decline in PSA value >50%, which is confirmed by a second value 3 or more weeks later (phase Ib expansion) [ Time Frame: Up to 3 years ] [ Designated as safety issue: No ]
  • Radiological Progression free survival – time from randomisation to disease progression based on central review in bone based on prostate cancer clinical trials working group 2 (PCWG2) guidelines, where applicable, or death (phase II) [ Time Frame: Up to 3 years ] [ Designated as safety issue: No ]
  • Radiological Progression free survival – time from randomisation to disease progression based on central review in soft tissue based on modified Response Evaluation Criteria Solid Tumours (RECIST) 1.1 where applicable, or death (phase II) [ Time Frame: Up to 3 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

  • Overall survival – defined as the time from randomisation to death from any cause (phase II) [ Time Frame: Up to 3 years ] [ Designated as safety issue: No ]
  • Time to prostate serum antigen (PSA) progression – defined as the date that a 25% or greater increase in PSA, and an absolute increase of 2 ng/mL or more from the nadir, is documented, which is confirmed by a second value 3 or more weeks later (phase II) [ Time Frame: Up to 3 years ] [ Designated as safety issue: No ]
  • Maximum decline in PSA – compared to baseline that occurs at any point after treatment start (phase II) [ Time Frame: Up to 3 years ] [ Designated as safety issue: No ]
  • Percentage change in PSA – from baseline to week 12 of treatment (phase II) [ Time Frame: Up to 3 years ] [ Designated as safety issue: No ]
  • PSA response – defined as a decline in PSA value >50%, which is confirmed by a second value 3 or more weeks later (phase II) [ Time Frame: Up to 3 years ] [ Designated as safety issue: No ]
  • CTC response – CTC reduction compared to baseline for at least one time point after treatment start assessed by CTC fall from, equal to, or more than, 5 to <5 cells per 7.5ml blood (phase II) [ Time Frame: Up to 3 years ] [ Designated as safety issue: No ]
  • CTC response-CTC reduction compared to baseline for at least one time point after treatment start assessed by maximum change in CTC counts compared to baseline that occurs at any point after treatment start (phase II) [ Time Frame: Up to 3 years ] [ Designated as safety issue: No ]
  • Radiological progression free survival – defined as time from randomisation to disease progression based on investigator assessment in bone based on PCWG2 or soft tissue based on modified RECIST 1.1 where applicable, or death (phase Ib expansion) [ Time Frame: Up to 3 years ] [ Designated as safety issue: No ]

 

Estimated Enrollment: 151

For phase II competetive enrollment and target for the Netherlands is to randomise 27 patients in 6 participating centres.

Study Start Date: November 2014
Estimated Study Completion Date: January 2018
Estimated Primary Completion Date: October 2017 (Final data collection date for primary outcome measure)

 

Arms Assigned Interventions
Experimental: BI 836845 & Enzalutamide (Arm A)

Approximately 60 patients

Drug: BI 836845 Drug: Enzalutamide
Active Comparator: Enzalutamide (Arm B)

Approximately 60 patients

Drug: Enzalutamide

 

Eligibility

Ages Eligible for Study: 18 Years and older
Genders Eligible for Study: Male
Accepts Healthy Volunteers: No

Criteria

Inclusion criteria:

  • The patient has histologically, or cytologically, confirmed adenocarcinoma of the prostate.
  • Male patient aged, equal to, or more than,18 years old.
  • Patients with radiographic evidence of metastatic prostate cancer (stage M1 or D2). Distant metastases evaluable by radionuclide bone scan, CT scan, or MRI within 28 days before the start of study treatment.
  • Patients with a prostate serum antigen (PSA), equal to, or more than, 20 ng/mL.
  • Patients with prior surgical or chemical castration with a serum testosterone of <50 ng/mL. If the method of castration is luteinizing hormone releasing level hormone (LHRH) agonists, the patient must be willing to continue the use of LHRH agonists during protocol treatment.
  • Eastern Cooperative Oncology Group performance status (ECOG PS) 0, 1 or 2.
  • Cardiac left ventricular function with resting ejection fraction >50% as determined by echocardiogram (ECHO) or multigated acquisition scan (MUGA).
  • Absolute neutrophil count (ANC) =1500/microlitre (uL).
  • Haemoglobin =9 g/dL.
  • Platelets =100,000/uL.
  • Bilirubin = 1.5 times the upper limit of normal (ULN).
  • Aspartate transaminase (AST) and alanine transaminase (ALT) = 2.5 times the ULN(or = 5 times the ULN if liver metastases are present).
  • Creatinine = 1.5 x ULN.
  • International normalized ratio (INR) </= 1.4 and a partial thromboplastin time (PTT) </= 5 seconds above the ULN (unless on oral anticoagulant therapy). Patients receiving full dose anticoagulation therapy are eligible provided they meet all other criteria, are on a stable dose of oral anticoagulant or low molecular weight heparin (except warfarin or coumarin-like anticoagulants, which are not permitted).
  • Fasting plasma glucose < 8.9 mmol/L (< 160 mg/dL) and HbA1c < 8.0%.

Inclusion criteria only for patients entering phase Ib escalation and phase II:

  • Patients who have disease progression during, or after, receiving docetaxel and have had at least 12 weeks of treatment and in the opinion of the investigator are unlikely to derive significant benefit from additional docetaxel-based therapy, or were intolerant to therapy with this agent.
  • Patients who have disease progression during, or after, receiving abiraterone treatment in any setting.
  • Patients must have progressive disease defined as at least one of the following:
    1. Progressive measurable disease: using conventional solid tumour criteria RECIST 1.1.
    2. Bone scan progression: at least two new lesions on bone scan, plus a rising PSA as described in (c) below.
    3. Increasing PSA level: at least two consecutive rising PSA values over a reference value (PSA #1) taken at least 1 week apart. A third PSA (PSA #3) is required to be greater than PSA #2; if not, a fourth PSA (PSA #4) is required to be greater than PSA #2.

Inclusion criterion only for patients entering phase Ib expansion cohort:

  • Patients must be receiving continuous enzalutamide treatment and show a rise in PSA level: at least two consecutive rising PSA values over a reference value (PSA #1) taken at least 1 week apart. A third PSA (PSA #3) is required to be greater than PSA #2; if not, a fourth PSA (PSA #4) is required to be greater than PSA #2.
  • Archive tumour tissue is available prior to recruitment for pharmacogenomic tests

Exclusion criteria:

  • Prior therapy with agents targeting Insulin Growth Factor (IGF) and/or Insulin Growth Factor Receptor (IGFR) pathway.
  • Patients that have been treated with any of the following within 4 weeks of starting trial treatment: chemotherapy, immunotherapy, biological therapies, molecular targeted, hormone therapy (except LHRH agonists), radiotherapy (except in case of localized radiotherapy for analgesic purpose or for lytic lesions at risk of fracture which can then be completed within 2 weeks prior to study treatment).
  • Use of any investigational drug within 4 weeks before start of trial treatment or concomitantly with this trial.
  • Patients that have been treated with strong cytochrome P450, family 2, subfamily C, polypeptide 8 (CYP2C8) inhibitors, CYP2C8 inducers, within 2 weeks of starting the trial treatment.
  • Corrected QT interval, Fridericia¿s (QTcF) prolongation > 450 ms or QT prolongation deemed clinically relevant by the investigator (e.g., congenital long QT syndrome). The QTcF will be calculated as the mean of the 3 ECGs taken at screening.
  • Patients with small cell or neuroendocrine tumours.
  • Patients with known or suspected leptomeningeal metastases.
  • Uncontrolled or poorly controlled hypertension.
  • Patients with poorly controlled diabetes mellitus. Patients with a history of diabetes are allowed to participate, provided that their blood glucose is within normal range (fasting < 160 mg/dL or below ULN) and that they are on a stable dietary or therapeutic regimen for this condition.
  • Known human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness.
  • Patients with epilepsy, seizures, or predisposing factors for seizure as judged by the investigator.
  • Patients unable to comply with the protocol as judged by the investigator.
  • Active alcohol or active drug abuse as judged by the investigator.
  • A history of allergy to human monoclonal antibodies.
  • Patients who are sexually active and unwilling to use a medically acceptable method of contraception, e.g. condom plus spermicide use for participating males, plus another form of birth control such as implants, injectables, combined oral contraceptives, intrauterine devices for female partners, during the trial and for at least three months after end of active therapy. Men unwilling to agree to not donate sperm while on trial drug and up to 6 months following the last dose of trial drug.
  • Previous or concomitant malignancies at any other site with the exception of the following:
    1. benign basal cell carcinoma
    2. benign low grade transitional cell carcinoma of the bladder
    3. other effectively treated malignancy that has been in remission for more than 5 years and is considered to be cured

Only for patients entering phase Ib dose escalation and phase II cohorts:

  • Patients who have received more than 2 prior non-docetaxel containing cytotoxic chemotherapy regimens for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
  • Patients who have received a taxane based treatment or abiraterone, within 4 weeks before start of study treatment.
  • Patients that have received prior enzalutamide in any setting will not be eligible.

Exclusion criterion only for patients entering phase Ib expansion cohort:

– Patients that have received prior taxane-based chemotherapy or abiraterone in any setting will not be eligible for the expansion cohort.

Additional exclusion criterion for patients undergoing tumour biopsy:

– For patients that are to undergo the tumour biopsy, a history of a hereditary bleeding disorder, or clinically relevant major bleeding event in the past 6 months, as judged by the investigator.

Additional relevant MeSH terms:

Prostatic Neoplasms
Prostatic Neoplasms, Castration-Resistant
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms

ClinicalTrials.gov processed this record on October 23, 2015

Deelnemende ziekenhuizen vindt u via de homepage (www.stichtingduos.nl), ga vervolgens naar ‘studies’ en onderaan in dit menu naar ‘ziekenhuizen enza/BI’. Ook kunt u op deze link klikken.

Klik hier voor Nederlandstalige informatie over deze studie.

© 2017, Stichting DUOS, redactie en teksten: Kuip&Ko, website: sbddesign.nldisclaimer   |   log in